Tag Archives: Hartaj Singh

Oppenheimer Maintains a Buy Rating on aTyr Pharma (LIFE)

Oppenheimer analyst Hartaj Singh maintained a Buy rating on aTyr Pharma (LIFE – Research Report) today and set a price target of $8.00. The company’s shares closed last Monday at $3.08, close to its 52-week low of $2.13. According to

Celsion (CLSN) Receives a Buy from Oppenheimer

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on Celsion (CLSN – Research Report), with a price target of $9.00. The company’s shares closed last Monday at $0.90, close to its 52-week low of $0.69.

Analysts Offer Insights on Healthcare Companies: Alexion Pharmaceuticals (NASDAQ: ALXN) and Planet 13 Holdings (Other OTC: PLNHF)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alexion Pharmaceuticals (ALXN – Research Report) and Planet 13 Holdings (PLNHF – Research Report). Alexion Pharmaceuticals (ALXN) Oppenheimer analyst Hartaj Singh maintained a

Oppenheimer Keeps Their Buy Rating on Sunesis Pharma (SNSS)

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on Sunesis Pharma (SNSS – Research Report), with a price target of $6.00. The company’s shares closed last Monday at $0.96. According to TipRanks.com, Singh is a

Oppenheimer Sticks to Their Buy Rating for Catabasis Pharmaceuticals (CATB)

In a report released today, Hartaj Singh from Oppenheimer reiterated a Buy rating on Catabasis Pharmaceuticals (CATB – Research Report), with a price target of $60.00. The company’s shares closed last Monday at $4.66, close to its 52-week low of

Oppenheimer Reaffirms Their Buy Rating on Cellectis SA (CLLS)

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on Cellectis SA (CLLS – Research Report), with a price target of $35.00. The company’s shares closed last Monday at $15.74. According to TipRanks.com, Singh is a